- Home
- VGZ vs BDTX Comparison
VGZ vs BDTX Comparison
Compare VGZ & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGZ | BDTX |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.7M | 220.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VGZ | BDTX |
|---|---|---|
| Price | $1.99 | $2.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.00 | ★ $10.17 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | N/A | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.12 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $1.20 |
| 52 Week High | $2.46 | $4.94 |
Technical Indicators
Market Signals| Indicator | VGZ | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 26.47 |
| Support Level | $1.89 | $3.67 |
| Resistance Level | $2.03 | $3.90 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | 0.04 | -0.12 |
| Stochastic Oscillator | 90.21 | 17.11 |
Price Performance
Historical ComparisonAbout VGZ Vista Gold Corp
Vista Gold Corp is a gold mining company. It is engaged in the evaluation, acquisition, exploration, and advancement of gold exploration and potential development projects. The company evaluate, acquire, explore and advance gold exploration and potential development projects for gold production or value adding strategic transactions. The Company has one reportable segment: Australia. The Australia segment conducts exploration, development, care and maintenance activities at Vista's asset, the Mt Todd gold project in Northern Territory, Australia.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.